→ Ed Kaye will now be transitioning out of Sarepta, as planned. The board announced this week that Doug Ingram will be taking over the Duchenne muscular dystrophy company. Ingram is the former president of Allergan, stepping out after the big merger with Actavis. He then went to run Chase, and sold the Alzheimer’s company to Allergan. Now he’ll be in charge of expanding sales for Sarepta’s Exondys 51 and running the pipeline as analysts speculate whether another M&A deal could be in the works.
→ André Choulika, the Paris-based CEO of Cellectis, has brought two well-known Novartis vets in as new directors of the CAR-T company. Novartis’ ex-commercial honcho Rainer Boehm is taking a seat alongside Hervé Hoppenot, the ex-oncology chief at Novartis who has been building Incyte.
→ Cambridge, MA-based Biogen has brought in Catherine Steele as its new communications chief. Steele had been communications chief at Novartis and began her career at Roche. She’ll be working with CEO Michel Vounatsos, who is building his own executive team at Biogen after taking the helm at the beginning of this year.
→ Adicet Bio in Menlo Park, CA, has appointed Jesse McGreevy as its chief medical officer. McGreivy is joining the company from Acerta, where he led the clinical development of acalabrutinib.
→ PPD has appointed Christopher Fikry as executive vice president of PPD Laboratories. Fikry joins PPD from Quest Diagnostics, where he served most recently as vice president and general manager for oncology and companion diagnostics.
→ Boston-based Regenacy Pharmaceuticals appointed Simon Jones as president and CEO, succeeding Walter Ogier, who will remain as a member of the company’s board.
→ Regenerative medicine stalwart Osiris Therapeutics has named Linda Palczuk as its new CEO. Palczuk had been a longtime staffer at AstraZeneca before going out on her own as a consultant.
→ Flexion Therapeutics recruited Mark Levine as senior vice president, general counsel and secretary.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.Free Subscription